Fig. 2: Tumour entities represented in the cohort and chromothripsis prevalence across entities.
From: The landscape of chromothripsis across adult cancer types
a Number of analysed cases for each tumour entity (n = 316 whole-genome sequences in total, with 263 cases for entities with at least 5 cases per entity). Tumour entities with less than 5 cases per entity are shown in Supplementary data 1. b Chromothripsis prevalence (high confidence) per tumour entity for all entities with at least 5 cases (n = 263). c Distribution of canonical versus non-canonical chromothripsis, from all cases with high confidence chromothripsis scoring (n indicates the number of high confidence chromothriptic cases per tumour entity for all entities with at least 5 high confidence cases). d Chromothripsis prevalence among cases with germline mutations in cancer predisposition genes (n = 74 cases, whole-genome and whole-exome sequences). Statistical significance was tested using Fisher exact test (*p < 0.05, two-sided). MPNST malignant peripheral nerve sheath tumour; GIST gastrointestinal stromal tumour; NOS not otherwise specified.
